Diabetes mellitus and prevention of late myocardial infarction after coronary Stenting in the randomized dual Antiplatelet therapy study

Circulation

Volumn 133, Issue 18, 2016, Pages 1772-1782

  Meredith, Ian T ^a   Tanguay, Jean François ^b   Kereiakes, Dean J ^c   Cutlip, Donald E ^d,e,f   Yeh, Robert W ^d,e,f   Garratt, Kirk N ^g   Lee, David P ^h   Steg, P Gabriel ^i,j   Weaver, W Douglas ^k   Holmes, David R ^l   Brindis, Ralph G ^m   Trebacz, Jaroslaw ⁿ   Massaro, Joseph M ^e,o   Hsieh, Wen Hua ^a   Mauri, Laura ^e,f,p  

^a MONASH UNIVERSITY   (Australia)

^b MONTREAL HEART INSTITUTE   (Canada)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g LENOX HILL HOSPITAL   (United States)

^h STANFORD UNIVERSITY   (United States)

ⁱ UNIVERSITÉ PARIS DESCARTES   (France)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k HENRY FORD HOSPITAL   (United States)

^l MAYO CLINIC   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ Jan Pawel II Hospital   (Poland)

^o BOSTON UNIVERSITY   (United States)

^p BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

diabetes mellitus; dual antiplatelet therapy; myocardial infarction; stents

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; INSULIN; PLACEBO; PRASUGREL; STREPTOKINASE; THIENOPYRIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BARE METAL STENTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY STENTING; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPEN STUDY; PATIENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; COMBINATION DRUG THERAPY; MYOCARDIAL INFARCTION;

AGED; ASPIRIN; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PYRIDINES;

EID: 84961391362     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.016783     Document Type: Article

References (28)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D., Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 434 444
2. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 339 229 234. doi: 10.1056/NEJM199807233390404.
3. Jensen LO, Maeng M, Thayssen P, Tilsted HH, Terkelsen CJ, Kaltoft A, Lassen JF, Hansen KN, Ravkilde J, Christiansen EH, Madsen M, Sørensen HT, Thuesen L., Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2012 109 629 635. doi: 10.1016/j.amjcard.2011.10.018.
4. Mohammadi S, Dagenais F, Mathieu P, Kingma JG, Doyle D, Lopez S, Baillot R, Perron J, Charbonneau E, Dumont E, Metras J, Desaulniers D, Voisine P., Long-term impact of diabetes and its comorbidities in patients undergoing isolated primary coronary artery bypass graft surgery. Circulation 2007 116 11 suppl I220 I225. doi: 10.1161/CIRCULATIONAHA.106.681320.
5. Ritsinger V, Saleh N, Lagerqvist B, Norhammar A., High event rate after a first percutaneous coronary intervention in patients with diabetes mellitus: results from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv 2015 8 e002328. doi: 10.1161/CIRCINTERVENTIONS.114.002328.
6. Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JC, Hoekstra JB., Hyperglycemia: a prothrombotic factor? J Thromb Haemost 2010 8 1663 1669. doi: 10.1111/j.1538-7836.2010.03910.x.
7. Grant PJ., Diabetes mellitus as a prothrombotic condition. J Intern Med 2007 262 157 172. doi: 10.1111/j.1365-2796.2007.01824.x.
8. Vazzana N, Ranalli P, Cuccurullo C, Davì G., Diabetes mellitus and thrombosis. Thromb Res 2012 129 371 377. doi: 10.1016/j.thromres.2011.11.052.
9. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH., 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011 124 e574 e651. doi: 10.1161/CIR.0b013e31823ba622.
10. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A., 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and The European Association for Cardio-thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014 35 2541 2619
11. Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, Wong G, Mehta SR, Canadian Cardiovascular Society Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol 2013 29 1334 1345. doi: 10.1016/j.cjca.2013.07.001.
12. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, Castriota F, Colombo F, Tebaldi M, Fucà G, Kubbajeh M, Cangiano E, Minarelli M, Scalone A, Cavazza C, Frangione A, Borghesi M, Marchesini J, Parrinello G, Ferrari R, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation 2012 125 2015 2026. doi: 10.1161/CIRCULATIONAHA.111.071589.
13. Gwon HC, Hahn JY, Park KW, Song YB, Chae IH, Lim DS, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK, Ahn T, Yoon JH, Jeong MH, Hong TJ, Chung WY, Choi YJ, Hur SH, Kwon HM, Jeon DW, Kim BO, Park SH, Lee NH, Jeon HK, Jang Y, Kim HS., Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation 2012 125 505 513. doi: 10.1161/CIRCULATIONAHA.111.059022.
14. Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmão M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL, OPTIMIZE Trial Investigators Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013 310 2510 2522. doi: 10.1001/jama.2013.282183.
15. Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G, ARCTIC investigators Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014 384 1577 1585. doi: 10.1016/S0140-6736(14)60612-7.
16. Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Kang TS, Park BE, Kang WC, Lee SH, Yoon JH, Hong BK, Kwon HM, Jang Y, RESET Investigators A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol 2012 60 1340 1348. doi: 10.1016/j.jacc.2012.06.043.
17. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, DAPT Study Investigators Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014 371 2155 2166. doi: 10.1056/NEJMoa1409312.
18. Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR, Bangalore S, Cutlip DE, Pencina M, Massaro JM., Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010 160 1035 41, 1041.e1. doi: 10.1016/j.ahj.2010.07.038.
19. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L, Dual Antiplatelet Therapy (DAPT) Study Investigators Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA 2015 313 1113 1121. doi: 10.1001/jama.2015.1671.
20. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007 115 2344 2351. doi: 10.1161/CIRCULATIONAHA.106.685313.
21. The GUSTO investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993 329 673 682
22. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H., Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011 123 2736 2747. doi: 10.1161/CIRCULATIONAHA.110.009449.
23. Schulz-Schüpke S, Byrne RA, Ten Berg JM, Neumann FJ, Han Y, Adriaenssens T, Tölg R, Seyfarth M, Maeng M, Zrenner B, Jacobshagen C, Mudra H, von Hodenberg E, Wöhrle J, Angiolillo DJ, von Merzljak B, Rifatov N, Kufner S, Morath T, Feuchtenberger A, Ibrahim T, Janssen PW, Valina C, Li Y, Desmet W, Abdel-Wahab M, Tiroch K, Hengstenberg C, Bernlochner I, Fischer M, Schunkert H, Laugwitz KL, Schömig A, Mehilli J, Kastrati A, Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Trial Investigators ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015 36 1252 1263. doi: 10.1093/eurheartj/ehu523.
24. Mauri L, Elmariah S, Yeh RW, Cutlip DE, Steg PG, Windecker S, Wiviott SD, Cohen DJ, Massaro JM, D'Agostino RB Sr, Braunwald E, Kereiakes DJ, DAPT Study Investigators Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016 37 378 385. doi: 10.1093/eurheartj/ehv614.
25. Bonaca MP, Scirica BM, Braunwald E, Wiviott SD, Goto S, Nilsen DW, Bonarjee V, Murphy SA, Morrow DA., New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol 2014 64 2318 2326. doi: 10.1016/j.jacc.2014.07.997.
26. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S., Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010 363 930 942
27. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM, TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 357 2001 2015. doi: 10.1056/NEJMoa0706482.
28. James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L, PLATO Study Group Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2010 31 3006 3016. doi: 10.1093/eurheartj/ehq325.